Title
Perampanel inhibition of AMPA receptor currents in cultured hippocampal neurons.

Permalink
https://escholarship.org/uc/item/8k91v930

Journal
PloS one, 9(9)

ISSN
1932-6203

Authors
Chen, Chao-Yin
Matt, Lucas
Hell, Johannes Wilhelm
et al.

Publication Date
2014

DOI
10.1371/journal.pone.0108021

Peer reviewed
Perampanel Inhibition of AMPA Receptor Currents in Cultured Hippocampal Neurons

Chao-Yin Chen1, Lucas Matt1, Johannes Wilhelm Hell1, Michael A. Rogawski2*

1 Department of Pharmacology, School of Medicine, University of California Davis, Davis, California, United States of America, 2 Department of Neurology, School of Medicine and Center for Neuroscience, University of California Davis, Sacramento, California, United States of America

Abstract

Perampanel is an aryl substituted 2-pyridone AMPA receptor antagonist that was recently approved as a treatment for epilepsy. The drug potently inhibits AMPA receptor responses but the mode of block has not been characterized. Here the action of perampanel on AMPA receptors was investigated by whole-cell voltage-clamp recording in cultured rat hippocampal neurons. Perampanel caused a slow (τ ~ 1 s at 3 μM), concentration-dependent inhibition of AMPA receptor currents evoked by AMPA and kainate. The rates of block and unblock of AMPA receptor currents were 1.5×10^6 M^−1 s^−1 and 0.58 s^−1, respectively. Perampanel did not affect NMDA receptor currents. The extent of block of non-desensitizing kainate-evoked currents (IC50, 0.56 μM) was similar at all kainate concentrations (3–100 μM), demonstrating a noncompetitive blocking action. Perampanel did not alter the trajectory of AMPA evoked currents indicating that it does not influence AMPA receptor desensitization. Perampanel is a selective negative allosteric AMPA receptor antagonist of high-affinity and slow blocking kinetics.

Citation: Chen C-Y, Matt L, Hell JW, Rogawski MA (2014) Perampanel Inhibition of AMPA Receptor Currents in Cultured Hippocampal Neurons. PLoS ONE 9(9): e108021. doi:10.1371/journal.pone.0108021

Editor: Jean-Pierre Mothet, CNRS - Université Aix Marseille, France

Received April 15, 2014; Accepted August 18, 2014; Published September 17, 2014

Copyright: © 2014 Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper.

Funding: This research was supported by grants from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health to MAR (NS072094), the National Institute on Aging of the National Institutes of Health to JWH (AG017502), and by Eisai. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: This research was supported, in part, by a grant from Eisai. MAR has served as a consultant to Eisai. None of the authors is an employee of Eisai. There are no restrictions on the authors’ adherence to PLOS ONE policies on sharing data and materials.

* Email: rogawski@ucdavis.edu

Introduction

AMPA receptors are members of the ionotropic glutamate receptor family of ligand-gated ion channels [1]. At excitatory synapses throughout the central nervous system, AMPA receptors play a key role as transducers of synaptic excitatory release glutamate into fast postsynaptic neuron depolarization. AMPA receptors also are critical to epileptic synchronization and the spread of epileptic seizures, so that pharmacological inhibitors of AMPA receptors have utility in the treatment of epilepsy [2,3]. The first type of selective AMPA receptor antagonist to be described were competitive antagonists, which bind to the recognition site for glutamate in the ligand binding domain (LBD), stabilizing a closed form of the channel by preventing closure of the clampshell-like LBD [4,5]. Shortly after the identification of competitive AMPA receptor antagonists, a second type of selective AMPA receptor antagonist was described that acts in a noncompetitive fashion with respect to agonists. These negative allosteric modulators include 2,3-benzodiazepines such as GYKI 52466 [6–9] and the related quinazolinone CP-465,022 [10], which bind within peptide segments of AMPA receptor subunits that link the LBD to the transmembrane spanning region [11]. Antagonist occupancy at this site inhibits the transduction of agonist binding into channel gating.

Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzotriazole] is a structurally novel AMPA receptor antagonist that is effective in the treatment of partial and secondarily generalized seizures in humans [12,13]. 2,4-Diphenyl-4H-1,3,4oxadiazin-5-one, the template molecule on which perampanel is based, was discovered by high throughput screening using a rat cortical neuron AMPA-induced cell death assay [14]. Systematic optimization of this template led to the discovery of perampanel, which exhibited high potency as an inhibitor of AMPA-induced Ca2+ influx in cultured rat cortical neurons (IC50, 0.093 μM) [15]. Studies to date have indicated that perampanel is highly selective. Even a high concentration (30 μM) only minimally inhibits NMDA responses and there is no evidence that perampanel interacts with other ion channel targets. In radioligand binding studies, [3H]perampanel binding to rat forebrain membranes was displaced by CP-463,022 and GKYI 52466, indicating that all three agents interact at a common (or allosterically-coupled) site on AMPA receptors. Perampanel has also shown selectivity for AMPA receptor mediated synaptic responses in recordings of field excitatory postsynaptic potentials in the CA1 area in rat hippocampal slices [16]. In these recordings, perampanel inhibited the AMPA receptor component of the field response (IC50, 0.23 μM), without affecting the NMDA or kainate receptor components.

While the information available to date is consistent with perampanel acting as a high potency AMPA receptor antagonist, complex effects on the concentration-response curve for AMPA in the Ca2+ influx assay have precluded a precise definition of the mode of inhibition [17]. Therefore, the objective in the present study was to characterize the blocking mechanism using whole cell patch
Table 1. IC50 Values for Perampanel Inhibition of AMPA- and Kainate-Evoked Currents.

| Agonist Concentration AMPA/kainate (µM) | AMPA Response IC50, Peak Current, (µM) | IC50, Late Current, (µM) | Kainate Response IC50 (µM) |
|---------------------------------------|--------------------------------------|--------------------------|--------------------------|
| 10/3                                  | 0.4                                  | 0.4                      | 0.58                     |
| 30/10                                 | 0.8                                  | 0.9                      | 0.51                     |
| 100/100                               | 0.9                                  | 1.2                      | 0.58                     |
| 10 µM vs. 30 µM                       | p = 0.0075                           | p < 0.0001               | 3 µM vs. 10 µM NS         |
| 10 µM vs. 100 µM                      | p = 0.0003                           | p < 0.0001               | 3 µM vs. 100 µM NS        |
| 30 µM vs. 100 µM                      | NS                                   | NS                       | 10 µM vs. 100 µM NS       |

IC50 values are the concentration of perampanel estimated to inhibit the current response by one-half, as determined by logistic fits to the mean percent of control values as presented in Fig. 1D and E, and Fig. 2B. To assess statistical significance of differences between the IC50 values, the perampanel concentration-response relationship was linearized. The concentration was log transformed and the current response was transformed as \( \log 10(Y) = \log [Y + c](Y_{max} - Y + c) \). Analysis of covariance models were used to estimate IC50 values. Differences among the IC50 values were tested for significance by comparing the response lines against a common response line, estimated without regard to the concentration. A Tukey-Cramer adjustment was used on those post hoc comparisons. NS, not significant.

doi:10.1371/journal.pone.0108021.t001

clamp techniques. The experimental paradigm also allowed us to define the blocking kinetics. Our results confirm that perampanel inhibits AMPA receptors in a noncompetitive fashion and demonstrate that the onset and recovery of block occurs slowly but is fully reversible.

Materials and Methods

Neuronal cultures

All experimental protocols in this work were reviewed and approved by the Institutional Animal Care and Use Committee of the University of California, Davis in compliance with the Animal Welfare Act and in accordance with Public Health Service Policy on the Humane Care and Use of Laboratory Animals.

Primary hippocampal neuronal cultures were prepared as previously described [18]. In brief, timed pregnant rats Sprague-Dawley rats (Charles River Laboratories International, Wilmington, MA, USA) were anesthetized with isoflurane. E18 embryos were obtained and the hippocampi were dissected and treated in Hank’s balanced salt solution (HBSS; Invitrogen, Carlsbad, CA, USA) with trypsin (0.03%, Sigma-Aldrich, St. Louis, MO) for 20 min at 37°C. After inactivation of trypsin with neuronal medium (Neurobasal medium; Invitrogen, Life Technologies, Grand Island, NY, USA) supplemented with NS21, 0.5 mM glutamine, 10 mM HEPES) plus 5% horse serum (HS; Invitrogen), the tissue was washed twice with HBSS, and triturated with a fire-polished Pasteur pipette. After non-disassociated pieces of tissue settled, cells in the supernatant were collected by centrifugation (1100 rpm at 200 x g for 3.5 min), re-suspended in neuronal medium plus 5% horse serum, counted, and plated on coverslips (Warner Instruments, Hamden, CT, USA) coated with 0.1% (w/v) poly-L-lysine (Peptides International, Louisville, KY, USA). The cell density was 3 x 10⁵ cm⁻² in plating medium. After 4 h, the medium was replaced with serum-free neuronal medium. Cells were grown in a humidified environment of 95% air/5% CO2 at 37°C. One third of medium was changed after 5 days in vitro (DIV) and weekly thereafter.

Voltage-clamp recording

Whole-cell voltage clamp experiments were performed 7–25 days after plating. For AMPA- and kainate-mediated currents, recordings were made in a bath solution containing 135 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, 1 µM tetrodotoxin (TTX), 10 µM bicuculline, 1 µM strychnine, and 500 nM MK-801. The pipette solution contained 145 CsCl, 0.1 mM CaCl2, 2 mM MgCl2, 1 mM EGTA, and 5 mM HEPES. For NMDA-mediated currents, recordings were made in a bath solution containing 135 mM NaCl, 5 mM KCl, 0.2 mM CaCl2, 10 mM HEPES, 1 µM TTX, 10 µM bicuculline, 1 µM strychnine, 10 µM NBQX, 3 mM glycine. The pipette solution contained 145 CsCl, 0.1 mM CaCl2, 1 mM EGTA, and 5 mM HEPES.

Recordings were made with an Axopatch 200B patch-clamp amplifier (Axon Instruments, Foster City, CA, USA). Whole-cell currents were filtered at 2 kHz and digitized at 10 kHz. All neurons were voltage-clamped at −60 mV. The following drugs dissolved in bath solution were applied using a fast perfusion system (VC5-8XP, ALA Scientific Instrument, NY, USA): kainate (3, 10, 100 µM), AMPA (10, 30, 100 µM), NMDA (10, 100 µM), and perampanel (0.01–30 µM). All were from Sigma-Aldrich except perampanel, which was from Eisai Inc. Solution reservoirs contained the drugs separately or the combination of an agonist (kainate, AMPA or NMDA) plus perampanel. Each solution reservoir was connected to a pinch valve of the 8-channel VC5-8XP perfusion system, which fed solution to an 8-to-1 manifold (MP-8, Warner Instruments, Hamden, CT) that has a dead-volume of 3.5 µl when switching between solutions. Only one perfusion line was open at a time. The opening speed was 15–20 ms. The command for switching among perfusion lines was generated by the pClamp software and delivered to the control box of the perfusion system via a TTL connection.

Statistical analysis

Data are expressed as means ± S.E.M. Differences were considered significant at \( p < 0.05 \). The statistical analyses were performed with SigmaStat software (SPSS Inc., Chicago, IL, USA), except that IC50 values were compared using SAS software (SAS Institute, Cary NC, USA) as described in the caption to Table 1.

Results

Perampanel inhibition of AMPA responses

Rapid perfusion of AMPA onto cultured hippocampal neurons at a holding potential of −60 mV elicited an inward current response that decayed rapidly to a steady-state level (Fig. 1A). Preapplication of perampanel for 5 s followed by coapplication of perampanel together with AMPA resulted in a reduction in the
amplitude of the peak and late AMPA response, where the late response is taken as the current amplitude at the end of the 5 s AMPA perfusion. The peak and late response amplitude were reduced to a similar extent. This is illustrated in Fig. 1B for recordings in the presence of 1 µM perampanel (which produced near half-maximal inhibition) where the mean ± S.E.M. peak to late ratio was not statistically different from control irrespective of the AMPA concentration. Similarly, as illustrated in Fig. 1C, 1 µM perampanel did not alter the rise time constant or decay time constant at any of the AMPA concentrations. The percent of control peak and late current amplitude values for various perampanel concentrations are plotted in Figs. 1D and E, respectively, for currents evoked by 10, 30 and 100 µM AMPA. Perampanel causes a concentration-dependent inhibition of the peak and late current responses. IC_{50} (half-maximum inhibition) values are 0.4, 0.8, and 0.9 µM for peak AMPA-induced currents for AMPA concentrations of 3, 30 and 100 µM, respectively. The corresponding IC_{50} values for late currents are 0.4, 0.9, and 1.2 µM. As shown in Table 1, there is a statistically significant difference in the IC_{50} values obtained with 10 µM AMPA and

Figure 1. Perampanel inhibition of AMPA-evoked currents in cultured hippocampal neurons. (A) Sample currents evoked by 100 µM AMPA in 4 neurons in the absence (left panels) and presence (right panels) of perampanel at the concentrations indicated demonstrating a concentration-dependent reduction in current. (B) Perampanel (1 µM) did not alter the mean values of the ratio of the peak to the late amplitude of currents evoked by 10, 30 and 100 µM AMPA in 7, 8 and 7 neurons, respectively, and (C) did not affect the mean rise time constant values or mean decay time constant values of the currents. Peak (D) and late (E) current values evoked by various AMPA concentrations expressed as percent of control prior to perampanel. Curves represent logistic fits to the data for each AMPA concentration. Peak current is the current during the last 100 ms of the perfusion. Data points in D and E represent mean ± S.E.M. of values from 3 to 9 neurons. Control values for peak/late ratio: 10 µM AMPA: 1.5±0.1; 30 µM AMPA: 1.7±0.1; 100 µM AMPA: 2.7±0.3. Control values for decay time constant (ms): 10 µM AMPA: 141±13; 30 µM AMPA: 93±7; 100 µM AMPA: 50±2. Control values for rise time (ms): 10 µM AMPA: 51±2; 30 µM AMPA: 45±3; 100 µM AMPA: 32±1.

doi:10.1371/journal.pone.0108021.g001
followed by coapplication of perampanel together with kainate current response (Fig. 2A). Preapplication of perampanel for 5 s neurons at a holding potential of –60 mV elicited a steady inward IC50 indicates an interaction between perampanel and AMPA bindings (see Discussion).

Kinetics of perampanel block

To assess the rate of perampanel block and unblock we initiated and terminated perampanel fast perfusion in the presence of the agonists kainate and AMPA as illustrated in Fig. 3. Fig. 3A shows sample traces from an experiment with kainate in one neuron. Fast perfusion of kainate 5 s after perampanel (3 μM) perfusion had been initiated resulted in a reduction of the kainate-induced current by ~73% (Fig. 3A2 versus Fig. 3A1), consistent with the results shown in Fig. 2. Concurrent application of kainate and perampanel (Fig. 3A3) resulted in a decaying current response suggesting the slow development of block over the 5 s combined perfusion. The peak initial current amplitude was modestly reduced from the initial control current amplitude as demonstrated by the summary value (bar A3) in Fig. 3C1. However the magnitude of the late current (bar A3 in Fig. 3C2) amplitude was not different from the magnitude of the late current with perampanel pretreatment (bar A2 in Fig. 3C2). These results demonstrate that perampanel block develops more slowly than channel activation but reaches a plateau that is similar to that achieved with perampanel pretreatment. Similar conclusions can be drawn from the paradigm of Fig. 3A4 where perampanel perfusion is initiated 5 s after the onset of kainate perfusion. The slow development of block (τ = 1.2±0.1 s) is clearly illustrated, as is the slow recovery from block (τ = 3.3±1.5 s).

Similar results were obtained when AMPA was used as the agonist, as illustrated in Fig. 3B. Fast perfusion of AMPA 5 s after the onset of perampanel resulted in reduction in the peak and late responses to a similar extent (~60%); Fig. 3B2). In contrast, when perampanel and AMPA were applied simultaneously, the peak response was reduced less (17%) than the late response (Fig. 3B3), suggesting that perampanel block is slow to develop. As the extent of late block is similar to the situation with pretreatment, full block is established within 5 s of the recording (Fig. 3D2, compare bar B3 with B2). The slow development of block is confirmed when perampanel perfusion is begun following preexposure to AMPA (Fig. 3B4); this exposure paradigm also demonstrates slow recovery of block of AMPA-evoked current.

The rate constants for binding and unbinding of perampanel were determined from experiments like those shown in Fig. 3B4 with perampanel concentrations of 1, 3 and 10 μM. Apparent rate constants for the approach to equilibrium block (kapp) were calculated as the reciprocal of the time constant values for the onset of block, which are shown in Fig. 4A. As demonstrated by the plot in Fig. 4B, kapp increases in a linear fashion with increasing perampanel concentration. Assuming a simple one-to-one binding reaction for block, kapp = k1[Perampanel]+k−1, where k1 and k−1 are the binding and unbinding rate constants, empirically determined from the best fit straight line to the data as 1.51±0.10×106 M−1 s−1 and 0.58±0.06 s−1, respectively. The mean off rate determined from the τoff values in Fig. 4A is 0.68 s−1, which is in good accordance with the value determined assuming a unimolecular binding reaction (intercept of straight line fit in Fig. 4B). The kinetically determined binding affinity (Kd = k−1/k1) is 3.9 μM.
Perampanel has no effect on NMDA responses

Rapid perfusion of 10 and 100 μM NMDA onto cultured hippocampal neurons at a holding potential of −60 mV elicited inward current responses that decayed modestly during the 5 s perfusion (Fig. 5A). Preapplication of perampanel (30 μM) for 5 s followed by coapplication of perampanel together with NMDA failed to affect the mean amplitudes of the peak (as in A1) with perampanel pre-application (as in A2), co-application (as in A3) and post-application (as in A4) in 3–4 neurons (D) Mean ± S.E.M. values of peak (D1) and late (D2) current levels as a percent of control (as in B1) with perampanel pre-application (as in B2), co-application (as in B3) and post-application (as in B4) in 4 neurons. *p<0.05 vs. A2 or B2.

doi:10.1371/journal.pone.0108021.g003

Figure 3. Slow onset and recovery from perampanel block of kainate- and AMPA-evoked currents. (A) Currents evoked by 100 μM kainate in the absence (A1) and with pre-application (A2), co-application (A2) and post-application (A3) of perampanel (3 μM) in the same neuron. (B) Currents evoked by 100 μM AMPA in the absence (B1) and with pre-application (B2), co-application (B2) and post-application (A3) of perampanel (3 μM) in a different neuron from (A). Open arrows indicate peak current levels in the case of AMPA-evoked currents and the current at 100 ms after onset of agonist application in the case of kainate-evoked currents; closed arrows indicate late current levels (end of agonist application). Scale for current is 300 pA in (A) and 500 pA in (B). (C) Mean ± S.E.M. values of peak (C1) and late (C2) current levels as a percent of control (as in A1) with perampanel pre-application (as in A2), co-application (as in A3) and post-application (as in A4) in 3–4 neurons.

Discussion

The results of the present study demonstrate that perampanel is a selective noncompetitive AMPA receptor antagonist. In neurons cultured from E18 rat embryos, kainate predominantly activates non-desensitizing or weakly-desensitizing AMPA receptor responses [19–22]. In addition, however, in some neurons smaller, rapidly desensitizing currents generated by kainate receptors are present. These currents desensitize completely and the speed of desensitization is so fast (τ ~ 20 ms) that they do not contribute in a meaningful way to the kainate currents observed in the slower time-scale recordings of the present study. Therefore, for practical purposes, the current responses generated by kainate can be assumed to be mediated by AMPA receptors. Because AMPA receptor currents activated by kainate do not desensitize or desensitize very rapidly to only a limited extent, they are well suited for studies on the mode and kinetics of block since complications caused by desensitization are avoided. In the present study, perampanel blocked kainate-evoked AMPA receptor current to a similar extent irrespective of the kainate concentration, confirming a noncompetitive (allosteric) blocking mechanism. The blocking potency (IC50, 0.56 μM) was comparable to that obtained in a previous study in brain slices [16].
The data is shown. The slope and the intercept values are plotted against perampanel concentration. The best-fit straight line to the data is shown. The slope and the intercept values are $1.5\pm0.1 \times 10^{6} \text{ M}^{-1} \text{s}^{-1}$ and $0.58\pm0.6 \text{ s}^{-1}$, respectively.

doi:10.1371/journal.pone.0108021.g004

A noteworthy observation in the present study is the slow rate at which perampanel block develops and at which unblock from activated receptors occurs. This is demonstrated in the experiments of Fig. 3 where preexposure to perampanel results in fully developed block but without preexposure block develops over the course of $\sim3$ s. The speed of block is slower than that obtained with 2,3-benzodiazepines. For example, block by GYKI 52466 at a concentration causing $\sim50\%$ inhibition of steady AMPA receptor current (30 µM) occurs in several hundred milliseconds [6,11]. The slower development of block by perampanel is largely due to the slower dissociation rate reflecting higher affinity binding to AMPA receptors. Thus, the association rates for GYKI 52466 [6] and perampanel (this study) are nearly identical at $1.6\times10^{7} \text{ M}^{-1} \text{s}^{-1}$ and $1.5\times10^{7} \text{ M}^{-1} \text{s}^{-1}$, respectively. However, the dissociation rate of GYKI 52466 (3.2 s$^{-1}$) is much faster than that of perampanel (0.58 s$^{-1}$) so that the approach to equilibrium representing the sum of the association and dissociation rates is slower for perampanel.

In sum, the present results support the conclusion that perampanel is a noncompetitive antagonist of AMPA receptor responses that acts in a similar fashion to structurally dissimilar 2,3-benzodiazepine and quinazolinone noncompetitive antagonists. However, perampanel is substantially more potent and exhibits correspondingly slower rates of onset and recovery from block. At steady-state (as is the case during chronic treatment for epilepsy), early and late AMPA receptor responses would be expected to AMPA receptors. Thus, the association rates for GYKI 52466 [6] and perampanel (this study) are nearly identical at $1.6\times10^{7} \text{ M}^{-1} \text{s}^{-1}$ and $1.5\times10^{7} \text{ M}^{-1} \text{s}^{-1}$, respectively. However, the dissociation rate of GYKI 52466 (3.2 s$^{-1}$) is much faster than that of perampanel (0.58 s$^{-1}$) so that the approach to equilibrium representing the sum of the association and dissociation rates is slower for perampanel.

In sum, the present results support the conclusion that perampanel is a noncompetitive antagonist of AMPA receptor responses that acts in a similar fashion to structurally dissimilar 2,3-benzodiazepine and quinazolinone noncompetitive antagonists. However, perampanel is substantially more potent and exhibits correspondingly slower rates of onset and recovery from block. At steady-state (as is the case during chronic treatment for epilepsy), early and late AMPA receptor responses would be expected to AMPA receptors. Thus, the association rates for GYKI 52466 [6] and perampanel (this study) are nearly identical at $1.6\times10^{7} \text{ M}^{-1} \text{s}^{-1}$ and $1.5\times10^{7} \text{ M}^{-1} \text{s}^{-1}$, respectively. However, the dissociation rate of GYKI 52466 (3.2 s$^{-1}$) is much faster than that of perampanel (0.58 s$^{-1}$) so that the approach to equilibrium representing the sum of the association and dissociation rates is slower for perampanel.

In sum, the present results support the conclusion that perampanel is a noncompetitive antagonist of AMPA receptor responses that acts in a similar fashion to structurally dissimilar 2,3-benzodiazepine and quinazolinone noncompetitive antagonists. However, perampanel is substantially more potent and exhibits correspondingly slower rates of onset and recovery from block. At steady-state (as is the case during chronic treatment for epilepsy), early and late AMPA receptor responses would be expected to AMPA receptors. Thus, the association rates for GYKI 52466 [6] and perampanel (this study) are nearly identical at $1.6\times10^{7} \text{ M}^{-1} \text{s}^{-1}$ and $1.5\times10^{7} \text{ M}^{-1} \text{s}^{-1}$, respectively. However, the dissociation rate of GYKI 52466 (3.2 s$^{-1}$) is much faster than that of perampanel (0.58 s$^{-1}$) so that the approach to equilibrium representing the sum of the association and dissociation rates is slower for perampanel.

In sum, the present results support the conclusion that perampanel is a noncompetitive antagonist of AMPA receptor responses that acts in a similar fashion to structurally dissimilar 2,3-benzodiazepine and quinazolinone noncompetitive antagonists. However, perampanel is substantially more potent and exhibits correspondingly slower rates of onset and recovery from block. At steady-state (as is the case during chronic treatment for epilepsy), early and late AMPA receptor responses would be expected to AMPA receptors. Thus, the association rates for GYKI 52466 [6] and perampanel (this study) are nearly identical at $1.6\times10^{7} \text{ M}^{-1} \text{s}^{-1}$ and $1.5\times10^{7} \text{ M}^{-1} \text{s}^{-1}$, respectively. However, the dissociation rate of GYKI 52466 (3.2 s$^{-1}$) is much faster than that of perampanel (0.58 s$^{-1}$) so that the approach to equilibrium representing the sum of the association and dissociation rates is slower for perampanel.

In sum, the present results support the conclusion that perampanel is a noncompetitive antagonist of AMPA receptor responses that acts in a similar fashion to structurally dissimilar 2,3-benzodiazepine and quinazolinone noncompetitive antagonists. However, perampanel is substantially more potent and exhibits correspondingly slower rates of onset and recovery from block. At steady-state (as is the case during chronic treatment for epilepsy), early and late AMPA receptor responses would be expected to AMPA receptors. Thus, the association rates for GYKI 52466 [6] and perampanel (this study) are nearly identical at $1.6\times10^{7} \text{ M}^{-1} \text{s}^{-1}$ and $1.5\times10^{7} \text{ M}^{-1} \text{s}^{-1}$, respectively. However, the dissociation rate of GYKI 52466 (3.2 s$^{-1}$) is much faster than that of perampanel (0.58 s$^{-1}$) so that the approach to equilibrium representing the sum of the association and dissociation rates is slower for perampanel.
current and are less potient inhibitors of late current (see ref. [24]).
Unlike the situation for noncompetitive antagonists, the blocking action of competitive antagonists can be overcome by high glutamate concentrations occurring during seizures. Theoretically, therefore, noncompetitive antagonists such as perampanel could have additivies of GABAergic/non-competitive antagonists in the treatment of epilepsy. In order for competitive antagonists to produce acceptable seizure protection, correspondingly higher doses might be required that would affect normal ongoing synaptic excitation leading to side effects. In fact, the available information indicates that perampanel provides clinically useful seizure protection with an acceptable side-effect profile.

References
1. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, et al. (2010) Glutamate receptor ion channel structure, regulation, and function. Pharmacol Rev 62: 405–496. DOI: 10.1124/pr.109.002451.
2. Lüscher W, Rogawski MA (2002) Epilepsy. In: Lodge D, Danyusz W, Parsons CG, editors. Ionotropic glutamate receptors as therapeutic targets. Johnson City, TN: F.P. Graham Publishing Co. 91–132.
3. Rogawski MA (2013) AMPA receptors as a molecular target in epilepsy therapy. Acta Neurol Scand Suppl 2013;197: 9–18. DOI: 10.1111/ane.12099.
4. Sheardown MJ, Niehen EO, Hansen AJ, Jacobsen P, Honore T (1990) 2,3-Dihydroxy-6-nitro-7-nitro-2,3-benzodiazepine (DNQX): a neuroprotectant for cerebral ischemia. Science 247: 571–574. DOI: 10.1126/science.2150493.
5. Högner A, Greenwood JR, Liljefors T, Lunn ML, Egelberg J, et al. (2003) Competitive antagonism of AMPA receptors by ligands of different classes: crystal structure of EFAPO bound to the GluR2 ligand-binding core, in comparison with DNQX. J Med Chem 46: 214–21. DOI: 10.1021/jm020989b.
6. Donevan SD, Rogawski MA (1993) GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron 10: 51–59. DOI: 10.1016/0896-6273(93)90241-I.
7. Sólyom S, Tarnawa I (2002) Non-competitive AMPA antagonists of 2,3-benzodiazepine type. Curr Pharm Des 8: 913–939. DOI: 10.2174/1381612924607081.
8. Ritz M, Wang C, Micale N, Nettai E, Niu L (2011) Mechanism of inhibition of the GluN2 AMPA receptor channel opening: the role of 4-methyl versus 4-carboxyl group on the diazepine ring of 2,3-benzodiazepine derivatives. ACS Chem Neurosci 2: 506–513. DOI: 10.1021/cn200033j.
9. Wang C, Han Y, Wu A, Sólyom S, Niu L (2013) Mechanism of inhibition of AMPA receptor channel opening: high affinity and selectivity of CP-465,022, a selective, noncompetitive AMPA receptor antagonist. Neuropharmacology 42: 143–153. DOI: 10.1016/S0028-3908(11)00170-0.
10. Balamut V, Menniti FS, Paternain AV, Lerma J, Sterrn-Bach Y (2005) Molecular mechanism of AMPA receptor noncompetitive antagonism. Neuron 48: 279–288. DOI: 10.1016/j.neuron.2005.09.024.
11. Steinhoff BJ, Ben-Menachem E, Rydin P, Shorvon S, Kramer L, et al. (2013) Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia 54: 1481–1489. DOI: 10.1111/epi.12212.
12. Krauss GL (2013) Perampanel: a selective AMPA antagonist for treating seizures. Epilepsia Curr 13: 269–272. DOI: 10.1065/epi.2012.12.22112.
13. Hibi S, Ueno K, Nagato S, Kasano K, Itô K, et al. (2012) Discovery of 2-(2-oxo-1-phenyl-2-pyrindin-3-yl)-1,2-dihydropryridin-3-ylbenzonitrile [perampanel]: a novel, noncompetitive α-aminoo-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) receptor antagonist. J Med Chem 55: 10584–11600. DOI: 10.1021/jm301269u.
14. Hanada T, Hashizume Y, Tokuhara N, Takeoka O, Kohmura N, et al. (2011) Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 52: 1331–1140. DOI: 10.1111/j.1528-1167.2011.03109.x.
15. Cecolin I, Bortolotto ZA, Rannetti C, Collingridge GL, Lodge D, et al. (2012) A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus. Neurochem Int 61: 517–522. DOI: 10.1016/j.neuint.2012.02.035.
16. Tokuhara N, Hatakeyama S, Amino H, Hanada T, Nishizawa Y (2008) Pharmacological profile of perampanel: a novel, non-competitive selective AMPA receptor antagonist. J Neurol 255: 173 (Abstract #P706). DOI: 10.1007/s00221-008-0901-9.
17. Chen Y, Stevens B, Chang J, Milbrandt J, Barres BA, et al. (2008) NS21: redefined and modified supplement B27 for neuronal cultures. J Neurosci Methods 171: 239–247. DOI: 10.1016/j.jneumeth.2008.03.013.
18. Lemme J, Paternain AV, Naranjo JR, Mellstrom B (1993) Functional kainate-selective glutamate receptors in cultured hippocampal neurons. Proc Natl Acad Sci USA 90: 11688–11692.
19. Patneau DK, Vyklicky I, Jr, Mayer ML (1993) Hippocampal neurons exhibit cyclothiazide-sensitive rapidly desensitizing responses to kainate. J Neurosci 13: 3496–3509.
20. Paternain AV, Morales M, Lerma J (1995) Selective antagonism of AMPA receptors unmasks kainate receptor-mediated responses in hippocampal neurons. Neuron 14: 185–189. DOI: 10.1016/0896-6273(95)90235-0.
21. Stern-Bach Y, Russo S, Neuman M, Rosenmund C (1998) A point mutation in the glutamate binding site blocks desensitization of AMPA receptors. Neuron 21: 907–918. DOI: 10.1016/S0896-6273(98)00605-4.
22. Armstrong N, Gouaux E (2000) Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core. Neuron 28: 165–181. DOI: 10.1016/S0896-6273(00)00094-5.
23. Parsons CG, Gruner R, Rozental J (1994) Comparative patch clamp studies on the kinetics and selectivity of glutamate receptor antagonism by 2,3-dihydroxy-6-nitro-7-sulamoyl-benzo{x}oquinone (NBQX) and 1-(4-aminophenyl)-4-methylpyridin-3-yl-7,8-methyl-endioxyl-5H-2,3-benzodiazepine (GYKI 52466). Neuropharmacology 33: 589–604. DOI: 10.1016/0028-3908(94)90163-5.
24. Donevan SD, Rogawski MA (1998) Allosteric regulation of α-aminoo-3-hydroxy-5-methyl-4-isoxazole-propanoic receptors by thiocyanate and cyclothiazide at a common modulatory site distinct from that of 2,3-benzodiazepines. Neurosci ence 87: 615–629. DOI: 10.1016/S0028-3908(98)00109-2.